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Fractures of the proximal femur are one of the greatest challenges facing the medical 
community, constituting a heavy socioeconomic burden worldwide. The National Hip 
Fracture Audit currently provides a framework for service evaluation. This evaluation is 
based upon the assessment of process rather than assessment of patient-centred outcome 
and therefore it fails to provide meaningful data regarding the clinical effectiveness of 
treatments. This study aims to capture data from the cohort of patients who present with a 
fracture of the proximal femur at a single United Kingdom Major Trauma Centre. Patient-
centred outcomes will be recorded and provide a baseline cohort within which to test the 
clinical effectiveness of experimental interventions.
Introduction
Fractures of the proximal femur are one of
the greatest challenges facing the medical
community. In 1990, a global incidence of
1.31 million was reported and was associ-
ated with 740 000 deaths.1 Proximal
femoral fractures constitute a heavy socio-
economic burden worldwide. The cost of
this clinical problem is estimated at
1.75 million disability adjusted life years
lost: 1.4% of the total healthcare burden in
established market economies.1 Acute
United Kingdom NHS Trusts are required to
follow-up and record data about all
patients admitted with a fracture of the
proximal femur as part of the National Hip
Fracture Database (NHFD) Audit.2 Cur-
rently, this audit provides a framework for
service evaluation. This evaluation is based
upon the assessment of process rather than
assessment of patient-centred outcome,
and therefore it fails to provide meaningful
data regarding the clinical effectiveness of
treatments. This study aims to capture data
from the cohort of patients who present
with a fracture of the proximal femur at the
University Hospitals Coventry and
Warwickshire NHS Trust, one of 22 Major
Trauma Centres in England. We will record
important patient-centred outcomes and
provide a baseline cohort within which to
test the clinical effectiveness of alternative
interventions.
Materials and Methods
Study design. This will be a cohort study that
will facilitate multiple embedded randomised
controlled trials as described by Relton et al.3
The study will be performed at a single Major
Trauma Centre (University Hospitals Coven-
try and Warwickshire NHS Trust) in the
United Kingdom. 
Ethical approval. This study has been reviewed
by the London – Camberwell St Giles Research
Ethics Committee (Ref: 11/LO/0927). The study
was given ethical approval on 18 August 2011.
The research will be carried out in compliance
with the Helsinki Declaration.
Study registration. This study has been reg-
istered with the International Standard
Randomised Controlled Trial Number Regis-
ter (ISRCTN 63982700) and the NIHR CRN
(Comprehensive Research Network) Portfolio
(UKCRN ID 12351).
Study participants. All patients aged
≥ 60 years with a fracture of the proximal
femur, including those with cognitive impair-
ment, are eligible for inclusion in this study.
This broad eligibility criterion should ensure
that the results of the study can be readily
generalised to the wider population of
patients with fracture of the proximal femur.
Age of 60 years is commonly used as a surro-
gate marker of bone density; i.e. patients
aged > 60 years represent those with a fragil-
ity fracture. Patients will be excluded if they
are deemed by the Consultant Trauma
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Surgeon to be medically unfit for an operation and are
treated non-operatively.
Recruitment. Patients will be recruited from trauma
meetings at University Hospitals Coventry and Warwick-
shire NHS Trust. Once an eligible patient is identified by
the responsible Consultant Trauma Surgeon they will be
referred to a research associate.
Timeline. The study commenced recruitment on 17 Jan-
uary 2012. Recruitment is planned to last for one year in
the first instance. Interim analyses as described in the sta-
tistical analysis will be reported as appropriate.
Consent. The large majority of patients with fracture of
the proximal femur are a clinical priority for urgent oper-
ative care. They will undergo surgery on the day of, or the
day following, admission. All patients with a fracture of
the proximal femur are in pain and many have received
opiate analgesia. It is therefore understandable that
patients often find the initial period of their treatment in
hospital confusing and disorientating. Similarly, patients’
next of kin, carers and friends are anxious at this time and
may also have difficulty in weighing the large amounts of
information that they are given about the injury and plan
for treatment.
In this emergency situation the focus lies with obtain-
ing consent for surgery (where possible) and informing
the patient and any next of kin about the immediate clin-
ical care. There is limited time for the patient, or if they
lack capacity their consultee, to review trial documenta-
tion and make an informed decision about whether they
would wish to participate.
Conducting research in this ‘emergency setting’ is regu-
lated by the Mental Capacity Act 2005.4 As patients are
likely to lack capacity as described above, and because of
the urgent nature of the treatment limiting access to, and
appropriate discussion with personal consultees, we will
act in accordance with section 32, subsection 9b of the
Mental Capacity Act. We will not obtain consent before
surgery but inform the patient and seek patient consent, or
consultee agreement, for continuation in the study at the
first appropriate time point in the post-operative period. 
At the first appropriate time when the patient has
regained capacity (this will usually be on the first day after
surgery) the research associate will provide the partici-
pant with all of the study information. The participant
will be given the opportunity to ask questions and dis-
cuss the study with their family and carers. They will then
be asked to provide written consent for follow-up within
the study.
For participants who do not regain capacity or lack
capacity, as a result of pre-fracture chronic cognitive
impairment, reasonable efforts will be made to identify a
Personal Consultee as described in the Mental Capacity
Act 2005. If no Personal Consultee can be identified then
a Nominated Consultee will be identified to advise the
research team. At all times the Chief Investigator will act
in accordance with the participants’ best interests.
Any new information that arises during the trial that
may affect participants’ willingness to take part will be
reviewed by the Programme Management Group; if nec-
essary this will be communicated to all participants. A
revised consent form will be completed if necessary.
Post-recruitment withdrawals and exclusions. Partici-
pants may withdraw from the study at any time without
prejudice. The General Practitioners of those participants
who are ‘lost to follow-up’ will be contacted in order to
attempt to complete the follow-up. Participants may be
withdrawn from the study at the discretion of the Chief
Investigator due to safety concerns. 
Study interventions. The standard-of-care treatment for
participants entering the cohort study will follow the
usual practice and pathways at the University Hospitals
Coventry and Warwickshire NHS Trust. This will be as
follows:
Pre-operative assessment. Participants will usually be
assessed in the Emergency Department. Diagnosis of a
fracture of the proximal femur will be confirmed by a plain
anteroposterior (AP) radiograph of the pelvis. Where there
is doubt over the radiological diagnosis, an additional
plain lateral hip radiograph may be taken. Where diagnos-
tic uncertainty remains, participants will be reviewed by
the on-call Orthopaedic Surgeon, and where clinically
indicated, a CT or MRI of the pelvis will be performed. For
participants who fall and sustain an injury to the proximal
femur while in hospital, a similar diagnostic protocol will
be followed, except that the responsible clinician will con-
duct the initial assessment on the inpatient ward.
Participants will be transferred to an Orthopaedic Trauma
ward. All participants will undergo the following investiga-
tions as a minimum: electrocardiogram, full blood count,
blood group and save, coagulation screen, urea, creatinine
and electrolytes. In accordance with Trust guidelines, partic-
ipants with haemoglobin less than 9 g/dl, or between 9 g/dl
and 9.9 g/dl and a history of ischaemic heart disease (IHD),
will be transfused to at least 10 g/dl; between 9 g/dl and
9.9 g/dl and no history of IHD will have two units of packed
red cells cross-matched and available intra-operatively. All
participants undergoing a blood product transfusion will
have a full blood count post-transfusion.
All patients will be assessed for venothromboembolic
risk. Where appropriate, chemo- and mechanical prophy-
laxis will be prescribed as per Trust guidelines. In partici-
pants with an international normalised ratio (INR) greater
than 6.5, advice will be sought immediately from the on-
call haematologist. Participants with an INR between 2 and
6.5 will receive vitamin K 1 mg intravenously (IV). Partici-
pants at low risk of complications of reversal (atrial fibrilla-
tion, recurrent thromboembolic event, thromboembolic
event more three months previously or thrombophilia) will
receive routine thromboprophylaxis after four hours.
Those at high risk (prosthetic heart valve, caval filter or
thromboembolic event less than three months previously)
will receive heparin via a standard IV infusion. Each
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participant will have their INR checked at 7 am on the day
of surgery. Participants with an INR greater than 2.5 will be
delayed for 24 hours and have their INR checked again; an
INR between 1.5 and 2.5 will receive two units of fresh fro-
zen plasma immediately pre-operatively; an INR less than
1.5 will undergo routine surgery.
Analgesia will be started from admission as 1 g
paracetamol oral or IV qds and 30 mg codiene phosphate
oral qds. These will continue during the nil-by-mouth
period. The participants’ regular anti-hypertensive, anti-
reflux (omeprazole, rantidine etc), anti-anginal and
bronchodilator therapies will be continued during the nil-
by-mouth period.
Anaesthetic technique. A regional or general anaesthe-
sia technique will be used for every participant at the
discretion of the senior attending anaesthetist. Intra-
operative analgesia will be achieved by combining a local
anaesthetic nerve block (femoral and lateral cutaneous
nerve of the thigh, fascia iliaca or lumbar plexus) using
either a nerve stimulator or ultrasound-guided tech-
nique, IV paracetamol 1 g intravenous infusion and opi-
ate analgesia as clinically indicated.
Operative intervention. Antibiotic prophylaxis will be
prescribed in accordance with Trust guidelines; partici-
pants who can tolerate penicillins will receive 1 g fluclox-
acillin and 3 to 5 mg/kg gentamicin at induction as an IV
infusion over 15 to 30 minutes. Penicillin-sensitive partic-
ipants will receive teicoplanin 600 mg, or 800 mg if body
mass is > 80 kg, as an IV bolus and 3 to 5 mg/kg gentami-
cin as an IV infusion over 15 to 30 minutes. Those who
have a positive methicillin-resistant Staphylococcus aureus
(MRSA) screen will be given the same prophylaxis as
those who are penicillin-sensitive.
Fractures will be classified pre-operatively from the
plain AP pelvis radiograph into four groups: 1) Minimally
displaced intracapsular – proximal to the trochanteric
line/crest5-7; 2) Displaced intracapsular – proximal to the
trochanteric line/crest5-7; 3) Trochanteric – distal to the
trochanteric line/crest and proximal to the lesser
trochanter5; and 4) Subtrochanteric – fractures located
principally in the 5 cm below the lesser trochanter.5
Group 1: Minimally displaced intracapsular fractures.
All participants will have their fracture fixed in situ. The
lower limb will be supported on a fracture table. Internal
fixation of the fracture will be achieved through a stan-
dard mini-open lateral or percutaneous approach with
two or three parallel cannulated screws.
Group 2: Displaced intracapsular fractures. Participants
will be positioned in the lateral position. The operating
surgeon will perform their preferred approach. The hip
will be dislocated and the head excised. A standard pol-
ished, tapered, modular head hemiarthroplasty femoral
component will be cemented into the femur using a third
generation cementing technique. The femoral head will
be applied and the arthroplasty reduced into the native
acetabulum.
A subgroup of these participants may be offered total
hip replacement (THR) where the acetabulum is also
replaced. Given the lack of evidence to support criteria to
select those participants who might benefit from THR,8 a
pragmatic approach will be adopted. The responsible
Consultant Trauma Surgeon will determine eligibility for
this subgroup, on the basis that he or she believes the par-
ticipant would benefit from THR. In the event of a partic-
ipant undergoing THR, the approach, implant and
operative technique employed would be at the discretion
of the operating surgeon.
Group 3: Trochanteric fractures. All participants will
have a closed reduction of their fracture. The lower limb
will be supported on a fracture table. Internal fixation of
the fracture will be achieved through a standard lateral
approach with a dynamic hip screw.
Group 4: Subtrochanteric fractures. All participants will
have a closed reduction of their fracture. The lower limb
will be supported on a fracture table. Internal fixation of
the fracture will be achieved through a standard lateral,
mini-open or percutaneous approach for nailing. Fixation
will be achieved using a long, distally locked, cephalo-
medullary device.
Post-operative rehabilitation. Post-operative analgesia
will be prescribed intra-operatively and reviewed by the
responsible clinical teams as appropriate. The initial post-
operative regimen will be: paracetamol 1 g oral or IV qds,
codeine phosphate 30 mg oral or IM for two days, lactu-
lose 20 mg oral bd, oramorph 10 mg every two hours prn
and buccal prochlorperazine 6 mg bd prn. In addition
oxygen 2l/min will be prescribed for two days. Prescribed
chemothromboprophylaxis will be continued for a period
of between 28 and 35 days.
Between 24 and 48 hours in the post-operative period
participants will undergo an initial Physiotherapy and
Occupational Therapy trauma assessment. A full social,
cognitive, premorbid function and falls history will be
obtained and documented. Participants will be given the
relevant University Hospitals Coventry and Warwickshire
NHS Trust Patient Information packs. An initial treatment
plan with objectives will be made, recorded and com-
menced. The aim of this plan will be for participants to
mobilise through early and active full-weight-bearing.
All participants will have a clinical review by a Specialist
Orthogeriatrician within 72 hours of admission. This will
include a fracture prevention assessment. Assessment
and treatment of participants’ for osteoporosis will be
carried out in accordance with current National Institute
of Health and Clinical Excellence (NICE) guidance,9 simi-
larly participants’ risk of falling in accordance with British
Orthopaedic Association (BOA) guidance.10
Social support and discharge requirements will be
identified as soon as possible. Identification and comple-
tion of relevant referrals will be made within seven days as
appropriate. Additionally, appropriate referrals to other
agencies or departments will be made to initiate or
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complete a falls prevention plan. Participants will be dis-
charged from the acute Orthopaedic Trauma Ward at the
earliest safe opportunity to the most appropriate dis-
charge destination as determined by the multidisciplinary
team. Final discharge from NHS facilities will be at the ear-
liest safe opportunity.
Follow-up. Following consent, participants will have
their pre-operative hip function, quality of life and physi-
cal activity level assessed through questionnaires (Euro-
Qol (EQ-5D),11 ICECAP(O)12-15 and Oxford hip score16).
This will be followed by telephone questionnaires at four
weeks, and four and 12 months post-operatively. For
those participants with cognitive impairment this assess-
ment will be limited to the EQ-5D, which will be reported
by an appropriate proxy. Participants and their consultees
will also be invited through a separate information sheet
and consent form to take part in semi-structured inter-
views at these time points. Where particpants have died
and the research team is aware (and the event already
recorded as an adverse event) no further follow-up is
attempted. If the research team is unaware then contact
will be made – for example out-of-area patients – and the
event of death recorded and further follow-up ceased.
In this study we will use techniques common in long-
term cohort studies to ensure minimum loss to follow-up.
Multiple contact addresses and telephone numbers,
mobile numbers and email addresses will be recorded dur-
ing enrolment. Considerable effort will be made by the
research team to keep in communication with participants.
We will attempt to contact the participant or next of kin
by telephone on three occasions, and then send them a
postal questionnaire invitation letter and questionnaire to
complete with a pre-paid envelope. Finally we will con-
firm contact details with the participant’s General Practi-
tioner. If all these methods fail then we will class the
participant as a non-responder for that time point.
Semi-structured interviews. Participants, both those with
and without cognitive impairment, and their carers will be
recruited for semi-structured interviews at each follow-up
time point (within one month, four months, one year post-
operatively). Participants and carers who have consented to
participate in a semi-structured interview on entry to the
study will be contacted by the project researcher to arrange
an interview. After completion of 15 to 20 interviews, the
team will review the EQ-5D scores and time points at inter-
view of the participants. Further purposeful sampling will
ensure, as far as is possible, that our final sample will
include a range of time points and EQ-5D scores. This pro-
cess will enable us to identify differences in the expecta-
tions and priorities of participants across different time
points in their recovery and for participants of differing
functioning and quality-of-life before their fracture. This
method of purposeful sampling will be continued (with
further review after approximately 30 interviews) until
approximately 45 interviews have been completed. Inter-
viewing will continue until data saturation has occurred.
Sample size. No formal sample size calculation has been
conducted for the comprehensive cohort study. However,
based upon data from the NHFD, between 500 and
600 patients with a fracture of the proximal femur can be
expected to be treated at University Hospitals Coventry
and Warwickshire NHS Trust each year. This will be an
ongoing study during which interim analyses will be per-
formed as appropriate.
Qualitative analysis. The interviews with participants
and their carers will be audio recorded, transcribed verba-
tim and analysed with the assistance of Nvivo 8 qualita-
tive data analysis software (QSR International Ltd,
Melbourne, Australia). Thematic analysis of interviews
will focus on participant expectations and priorities.
Interview participants’ scores on the measurement tools,
as well as their thoughts and reflections on the ease of use
of the tool will be analysed in line with their interview
transcript. In particular, the team will focus on whether
the themes identified from the interviews are adequately
captured by the measurement tools, and crucially,
whether there are themes that are missed by the tool but
are nevertheless important to patients experiencing frac-
ture of the proximal femur. Thus, interview participants’
scores on the measurement tools will be treated as part of
the qualitative data. 
Reporting plan
This study is expected to report its initial findings in
March 2013.
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